NASDAQ:IOVA

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

$7.69

-0.05 (-0.65%)

(As of 01/26/2023 05:17 PM ET)

Add

Compare

Today's Range: $7.43
▼
$7.88
50-Day Range: $5.62
▼
$8.03
52-Week Range: $5.42
▼
$18.73

Volume: 5.46 million shs
Average Volume: 5.22 million shs
Market Capitalization: $1.21 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.73

Institutional Ownership

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.58 Rating Score
Upside/Downside: 160.6% Upside
$19.73 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.89
Upright™ Environmental Score
News Sentiment: 0.59
Based on 13 Articles This Week
Insider Trading: Acquiring Shares
$65.19 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.50) to ($2.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

76th out of 1,048 stocks

Biological Products, Except Diagnostic Industry

12th out of 168 stocks

4.3

Analyst's Opinion

Consensus Rating
Iovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.58, and is based on 7 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.73, Iovance Biotherapeutics has a forecasted upside of 160.6% from its current price of $7.57.
Amount of Analyst Coverage
Iovance Biotherapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for IOVA.

0.0

Dividend Strength

Dividend Yield
Iovance Biotherapeutics does not currently pay a dividend.
Dividend Growth
Iovance Biotherapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Iovance Biotherapeutics has received a 72.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.
Environmental Sustainability
The Environmental Impact score for Iovance Biotherapeutics is -0.89.

2.0

News and Social Media Coverage

News Sentiment
Iovance Biotherapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Iovance Biotherapeutics this week, compared to 1 article on an average week.
Search Interest
Only 21 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,190,280.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.60% of the stock of Iovance Biotherapeutics is held by insiders.
Percentage Held by Institutions
96.78% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($2.50) to ($2.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iovance Biotherapeutics is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iovance Biotherapeutics is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Iovance Biotherapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

January 26, 2023 | americanbankingnews.com

Truist Financial Increases Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $17.00

January 25, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Iovance Biotherapeutics (IOVA), Elevance Health (ELV)

January 26, 2023 | Investing Trends (Ad)

YIKES! 220 Pounds of Graphite in Each EV Battery?

Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.

January 24, 2023 | msn.com

The Latest Analyst Ratings for Iovance Biotherapeutics

January 24, 2023 | finance.yahoo.com

Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%

January 23, 2023 | finance.yahoo.com

Why Iovance Biotherapeutics Stock Soared 12% Higher Today

January 23, 2023 | finance.yahoo.com

Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates

January 19, 2023 | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to Post Q1 2023 Earnings of ($0.59) Per Share, Oppenheimer Forecasts

January 26, 2023 | PressReach (Ad)

Stocks News Announcement

Don't miss this update. Read the press release about Small Pharma.

January 13, 2023 | marketwatch.com

Tumor Infiltrating Lymphocyte (TIL) Market is booming in near Future 2023-2029

January 12, 2023 | marketwatch.com

Neoantigen Targeted Therapies Market 2023 : Incredible Possibilities, Growth Analysis and Forecast To 2028

December 11, 2022 | finance.yahoo.com

Trade Alert: The Independent Director Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), Wayne Rothbaum, Has Just Spent US$65m Buying 124% More Shares

December 5, 2022 | marketwatch.com

Iovance Biotherapeutics Stock Up 20% After Director Buys 10M Shares

December 5, 2022 | seekingalpha.com

Why did Iovance Biotherapeutics stock climb today? $65M insider buy

December 1, 2022 | benzinga.com

63K Reasons To Be Bullish On Iovance Biotherapeutics Stock

November 29, 2022 | benzinga.com

Iovance Biotherapeutics Recent Insider Activity

November 21, 2022 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)

November 18, 2022 | markets.businessinsider.com

Iovance Declines Following FDA Feedback On Its Melanoma Drug Lifileucel

November 18, 2022 | markets.businessinsider.com

Robert W. Baird Keeps Their Buy Rating on SAB Biotherapeutics (SABS)

November 4, 2022 | msn.com

Recap: Iovance Biotherapeutics Q3 Earnings

November 2, 2022 | msn.com

Preview: Iovance Biotherapeutics's Earnings

October 10, 2022 | finance.yahoo.com

Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy

September 27, 2022 | seekingalpha.com

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

September 10, 2022 | seekingalpha.com

IOVA Iovance Biotherapeutics, Inc.

September 6, 2022 | finance.yahoo.com

Iovance Biotherapeutics to Present Posters at ESMO 2022

September 5, 2022 | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Rating of "Moderate Buy" from Analysts

September 5, 2022 | msn.com

As Philly becomes a hub for life sciences, a new program will train workers for jobs in the field

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings: 11/03/2022
Today: 1/26/2023
Next Earnings (Estimated): 2/23/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IOVA
CUSIP: N/A
CIK: 1425205
Web: www.iovance.com
Phone: (650) 260-7120
Fax: N/A
Employees: 319
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.73
High Stock Price Forecast: $38.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +156.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.58
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-342,250,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -76.45%
Return on Assets: -59.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.67
Quick Ratio: 4.67

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.96 per share
Price / Book: 1.94

Miscellaneous

Outstanding Shares: 157,841,000
Free Float: 145,845,000
Market Cap: $1.21 billion
Optionable: Optionable
Beta: 0.38

Key Executives

Frederick G. Vogt
President, CEO, Secretary & General Counsel

Igor P. Bilinsky
Chief Operating Officer

Jean-Marc Bellemin
CFO & Principal Accounting Officer

Friedrich Graf Finckenstein
Chief Medical Officer

Kristin Lanzi
Vice President-Information Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings or view top-rated stocks.
What is Iovance Biotherapeutics' stock price forecast for 2023?: 12 Wall Street research analysts have issued 1-year price objectives for Iovance Biotherapeutics' shares. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they anticipate the company's stock price to reach $19.73 in the next year. This suggests a possible upside of 159.2% from the stock's current price.
View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts.
How have IOVA shares performed in 2023?: Iovance Biotherapeutics' stock was trading at $6.39 on January 1st, 2023. Since then, IOVA shares have increased by 19.1% and is now trading at $7.61.
View the best growth stocks for 2023 here.
When is Iovance Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our IOVA earnings forecast.
How were Iovance Biotherapeutics' earnings last quarter?: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.01.
What other stocks do shareholders of Iovance Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?: Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."
Who are Iovance Biotherapeutics' major shareholders?: Iovance Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (0.52%), Peregrine Capital Management LLC (0.19%), Hennion & Walsh Asset Management Inc. (0.11%) and Foundations Investment Advisors LLC (0.01%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends.
How do I buy shares of Iovance Biotherapeutics?: Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Iovance Biotherapeutics' stock price today?: One share of IOVA stock can currently be purchased for approximately $7.61.
How much money does Iovance Biotherapeutics make?: Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.20 billion. The biotechnology company earns $-342,250,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.
How many employees does Iovance Biotherapeutics have?: The company employs 319 workers across the globe.
How can I contact Iovance Biotherapeutics?: Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 1/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

Iovance Biotherapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

IOVA Stock News Headlines

IOVA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IOVA Stock - Frequently Asked Questions

Overall MarketRank^™